UiPath Inc. (NYSE:PATH) Receives $17.71 Average Price Target from Brokerages

Shares of UiPath Inc. (NYSE:PATH) have earned an average rating of “Hold” from the eighteen analysts that are presently covering the stock, MarketBeat.com reports. Sixteen research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $17.71.

A number of analysts recently issued reports on PATH shares. BMO Capital Markets raised their target price on shares of UiPath from $14.00 to $15.00 and gave the stock a “market perform” rating in a research report on Friday, September 6th. Morgan Stanley restated an “equal weight” rating and issued a $15.00 price target on shares of UiPath in a report on Friday, September 6th. Bank of America increased their price objective on shares of UiPath from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Friday, September 6th. Wells Fargo & Company upped their price target on shares of UiPath from $14.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Friday, September 6th. Finally, TD Cowen cut their price target on shares of UiPath from $17.00 to $16.00 and set a “hold” rating on the stock in a research note on Friday, September 6th.

UiPath Price Performance

Shares of NYSE PATH opened at $11.95 on Tuesday. UiPath has a 12-month low of $10.37 and a 12-month high of $27.87. The company has a market capitalization of $6.57 billion, a PE ratio of -74.69 and a beta of 0.87. The firm’s 50-day moving average is $12.18 and its two-hundred day moving average is $15.27.

UiPath (NYSE:PATH) last posted its earnings results on Thursday, September 5th. The healthcare company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. UiPath had a negative return on equity of 3.98% and a negative net margin of 8.13%. The firm had revenue of $316.00 million for the quarter, compared to analyst estimates of $303.69 million. During the same quarter in the prior year, the company earned ($0.09) EPS. UiPath’s revenue was up 10.0% on a year-over-year basis. On average, analysts forecast that UiPath will post -0.23 EPS for the current fiscal year.

Insider Transactions at UiPath

In related news, CFO Ashim Gupta sold 47,671 shares of the firm’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $12.07, for a total transaction of $575,388.97. Following the sale, the chief financial officer now directly owns 849,917 shares in the company, valued at approximately $10,258,498.19. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 22.37% of the company’s stock.

Institutional Investors Weigh In On UiPath

Large investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. boosted its position in UiPath by 50.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 19,135 shares of the healthcare company’s stock valued at $475,000 after buying an additional 6,385 shares during the last quarter. Corient Private Wealth LLC raised its position in shares of UiPath by 8.7% in the 4th quarter. Corient Private Wealth LLC now owns 34,480 shares of the healthcare company’s stock valued at $856,000 after purchasing an additional 2,756 shares in the last quarter. Hsbc Holdings PLC boosted its stake in shares of UiPath by 14.8% during the 4th quarter. Hsbc Holdings PLC now owns 98,725 shares of the healthcare company’s stock valued at $2,455,000 after buying an additional 12,691 shares during the last quarter. Treasurer of the State of North Carolina boosted its stake in shares of UiPath by 2.3% during the 4th quarter. Treasurer of the State of North Carolina now owns 168,768 shares of the healthcare company’s stock valued at $4,192,000 after buying an additional 3,780 shares during the last quarter. Finally, California State Teachers Retirement System grew its position in shares of UiPath by 5.3% during the fourth quarter. California State Teachers Retirement System now owns 565,216 shares of the healthcare company’s stock worth $14,040,000 after buying an additional 28,435 shares in the last quarter. 62.50% of the stock is owned by institutional investors and hedge funds.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.